ACQUISITIONS AND DISPOSITIONS (Details) $ in Thousands				1 Months Ended		3 Months Ended	12 Months Ended
	Nov. 07, 2017 USD ($)	Nov. 17, 2015 USD ($) patent	Apr. 02, 2015 USD ($)	Jan. 31, 2018	Nov. 30, 2017 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
ACQUISITIONS AND DISPOSITIONS
Gain on divestiture							$ 17,064
Purchase price consideration
Cash Paid									$ 1,050,011
Research and development expenses							$ 13,718	$ 32,631	$ 17,541
Endo
ACQUISITIONS AND DISPOSITIONS
Number of patents infringed | patent		3
Slan | License Agreement
ACQUISITIONS AND DISPOSITIONS
License agreement term (in years)	10 years
License fee	$ 5,000
Company's marketing and selling term (in years)	7 years
Slan's selling term after the Company's (in years)	3 years
Purchase price consideration
Research and development expenses	$ 24,900
Cebranopadol
ACQUISITIONS AND DISPOSITIONS
Period of time written notice of termination (in days)				120 days
Purchase price consideration
Cash Paid		$ 25,000
Research and development expenses		54,900
Cebranopadol | Endo
Purchase price consideration
Amount of one-time accounting adjustment		29,900
Cebranopadol | Endo | Non-cash gain on settlement agreement
Purchase price consideration
Amount of one-time accounting adjustment		(29,900)
Cebranopadol | Endo | Acquired in-process research and development expense
Purchase price consideration
Amount of one-time accounting adjustment		$ 29,900
NUCYNTA
Purchase price consideration
Cash Paid			$ 1,050,000
Rebates Payable By Seller			9,977
Total Purchase Consideration			1,040,023
Amount of decrease in the rebate payment						$ 500
Amount of rebate payable estimated on the acquisition date			10,500
Increase in the purchase consideration and fair value of NUCYNTA U.S product rights						$ 500
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Intangible asset - acquired entity product rights			1,019,978
Inventories			11,590
Manufacturing Equipment			8,455
Total			$ 1,040,023
Other information
Estimated useful life of intangible asset			10 years
Business acquisition step up in value of inventories			$ 5,900
NUCYNTA | Selling general and administrative expense
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Business Combination, Acquisition Related Costs								$ 12,300
Lazanda
ACQUISITIONS AND DISPOSITIONS
Gain on divestiture					$ 17,100